10-K: Aclarion, Inc. Files 10-K Report for Fiscal Year 2023, Outlines Financials and Strategic Outlook

Aclarion, Inc. released its 10-K filing for fiscal year 2023, detailing its financial performance, strategic initiatives, and future outlook in the healthcare technology sector.

Summary

• Aclarion, Inc. reported a net loss of $4.9 million for fiscal year 2023, compared to a net loss of $7.1 million in 2022.
• The company's revenue increased to $75,404 in 2023 from $60,444 in 2022, primarily due to growing utilization of Nociscan in third-party clinical studies.
• Operating expenses decreased to $4.9 million in 2023 from $5.6 million in 2022, mainly due to reduced research and development costs and lower general and administrative expenses.
• The company's cash position was approximately $1.0 million as of December 31, 2023, with subsequent capital raises expected to fund operations into the third quarter of 2024.
• Aclarion is focused on securing payer contracts for its Nociscan technology and expanding its market reach through strategic partnerships and clinical studies.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as increased revenue and reduced losses, the company faces significant challenges including a material weakness in internal controls, limited cash runway, and dependence on a single vendor. The need for additional funding and the risks associated with commercialization and market adoption temper the overall sentiment.

Positives

• The company experienced a reduction in net losses year-over-year.
• Revenue increased due to growing utilization of Nociscan in clinical studies.
• Operating expenses decreased due to reduced research and development costs and lower general and administrative expenses.
• Aclarion has secured strategic partnerships with ATEC Spine, Inc. and continues to collaborate with Siemens.
• The company is actively working to secure payer contracts and expand its market reach.

Negatives

• The company has a history of net losses and expects to continue incurring losses for the foreseeable future.
• A material weakness in internal control over financial reporting has been identified.
• The company's current cash resources are expected to fund operations only into the third quarter of 2024.
• The company is dependent on a limited number of MR scanner models provided by SIEMENS.
• The company is reliant on a single clinical study at a single clinical center involving one spine surgeon who has a financial interest in the Company.

Risks

• The company may not be able to maintain compliance with Nasdaq listing requirements, potentially leading to delisting.
• The company's commercial success depends on market acceptance of its technology among patients, clinicians, and imaging facilities.
• The company's products are currently compatible with a limited number of MR scanners, limiting its market reach.
• The company may not be able to obtain, maintain, protect, enforce, and defend its intellectual property rights.
• The company may face competition from other diagnostic options for low back pain.
• The company's ability to grow sales depends on adequate reimbursement from third-party payers.
• The company's collection, use, and storage of sensitive information could lead to liabilities and other risks.
• The company's current product is supported by a single clinical study at a single clinical center.
• The company's current processes are not optimized to support the scaling of its technology.

Future Outlook

Aclarion plans to secure payer contracts, expand its market reach, and continue clinical studies to support the adoption of its Nociscan technology. The company also intends to expand its technology to address neck pain and other clinical applications.

Management Comments

• The company is focused on securing payer contracts to cover its Category III CPT codes.
• The company believes that with favorable payer coverage, it has the opportunity to more efficiently engage physicians and imaging centers that will adopt its technology.
• The company plans to track patients through clinical registries to build on early clinical evidence.

Industry Context

Aclarion is operating in the $134.5 billion U.S. low back and neck pain market, which is the most costly healthcare condition in the United States. The company's technology aims to address the lack of objective, cost-effective, and noninvasive diagnostics for identifying the source of patients' pain.

Comparison to Industry Standards

• Aclarion's technology is positioned as a non-invasive alternative to the Provocation Discogram test, which is invasive, subjective, and unpleasant for patients.
• The company's technology aims to improve surgical outcomes for discogenic low back pain patients, where current surgical success rates range from 41% to 57%.
• Aclarion's technology is designed to enhance the diagnostic value of standard lumbar MRI exams, which are often unreliable for identifying painful discs.
• The company's technology is compatible with certain Siemens MR scanner models, which limits its current market reach compared to companies with broader compatibility.
• Aclarion's technology is being evaluated in NIH-funded studies, such as the BACPAC and BEST initiatives, which are designed to evaluate technologies for predicting optimal treatment paths for back pain patients.

Related Party Transactions

• The company has an exclusive license agreement with the Regents of the University of California, which includes royalty payments.
• The company has entered into a number of investment and commercial transactions with Nuvasive.
• SC Capital 1 LLC and Clark Gunderson, M.D. have invested in the company's Series B-1 preferred stock financing and 6% convertible preferred note financing.
• The company entered into a securities purchase agreement with Jeffrey Thramann, our Executive Chairman, for the issuance of one share of Series A Preferred Stock.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial performance and ability to secure funding.
• Customers (physicians and imaging centers) will benefit from the company's efforts to secure payer contracts and expand market reach.
• Patients may benefit from improved diagnostic accuracy and treatment outcomes with the use of the company's technology.
• Suppliers and creditors may be affected by the company's financial stability and ability to meet its obligations.

Next Steps

• The company plans to secure payer contracts to cover its Category III CPT codes.
• The company intends to expand its market reach through strategic partnerships and clinical studies.
• The company will continue to develop and execute clinical studies to support label retention and expansion for additional indications.
• The company plans to expand its technology to address neck pain and other clinical applications.

Key Dates

Keywords

Nociscan, Magnetic Resonance Spectroscopy, Low Back Pain, Discogenic Pain, CPT Codes, Healthcare Technology, Spine Surgery, Medical Device, Reimbursement, AI, Machine Learning, Biomarkers